ライフサイエンスコーパス: fibrillation

1 ained ventricular tachycardia or ventricular fibrillation).

2 ary heart disease, heart failure, and atrial fibrillation).

3 ary heart disease, heart failure, and atrial fibrillation).

4 anticoagulation use in patients with atrial fibrillation.

5 using the framework: hypertension and atrial fibrillation.

6 calcitonin prevents both atrial fibrosis and fibrillation.

7 s is a major contributor to sustained atrial fibrillation.

8 dial remodeling that paves the way of atrial fibrillation.

9 ional associations between height and atrial fibrillation.

10 ke/systemic embolism in patients with atrial fibrillation.

11 cardioembolic stroke attributable to atrial fibrillation.

12 n to contribute to the development of atrial fibrillation.

13 ncreased incidence of ventricular and atrial fibrillation.

14 result in an antiarrhythmic effect on atrial fibrillation.

15 tional cardiovascular risk factors on atrial fibrillation.

16 6,587 ESKD hemodialysis patients with atrial fibrillation.

17 een disease-related mutations, LLPS, and tau fibrillation.

18 has also been associated with risk of atrial fibrillation.

19 triggers in patients with paroxysmal atrial fibrillation.

20 erotic CVD, stroke, heart failure and atrial fibrillation.

21 lse IRE PV isolation in patients with atrial fibrillation.

22 with atrial voltage in patients with atrial fibrillation.

23 nanofibrils and impact of polyols on protein fibrillation.

24 rogram abnormalities in patients with atrial fibrillation.

25 lation is considered in patients with atrial fibrillation.

26 ecurrence in patients with paroxysmal atrial fibrillation.

27 el TASK-1 as a therapeutic target for atrial fibrillation.

28 ed cognitive decline in patients with atrial fibrillation.

29 l abnormalities including the risk of atrial fibrillation.

30 ne of the management of patients with atrial fibrillation.

31 ablation in patients with persistent atrial fibrillation.

32 nts admitted with ischemic stroke and atrial fibrillation.

33 ay offer new targets for treatment of atrial fibrillation.

34 vein (PV) isolation in patients with atrial fibrillation.

35 ker release, myocardial fibrosis, and atrial fibrillation.

36 gnificantly associated with new-onset atrial fibrillation.

37 rosis and increases susceptibility to atrial fibrillation.

38 rsistent and long-standing persistent atrial fibrillation.

39 e of kidney function in patients with atrial fibrillation.

40 therapeutic avenues for patients with atrial fibrillation.

41 ants associated with ECG measures and atrial fibrillation.

42 ght and a large biobank-based GWAS of atrial fibrillation.

43 atients with OHCA and refractory ventricular fibrillation.

44 minating ventricular tachycardia/ventricular fibrillation.

45 egation propensity, reducing the rate of its fibrillation.

46 s from 358 patients with nonrecurrent atrial fibrillation (1-3 mm interspace per slice, 20-200 slices

47 use were: 1.69 (95% CI 1.54-1.85) for atrial fibrillation, 1.75 (95% CI 1.56-1.97) for heart failure,

48 ials for obstructive sleep apnoea and atrial fibrillation(16).

49 yocardial infarction, 180 strokes, 65 atrial fibrillation, 29 revascularizations, and 246 CVD deaths;

50 ock or complete heart block; (3) ventricular fibrillation; (4) ventricular tachycardia (>15 beats); (

51 hythm (atrial fibrillation 8.03:1; no atrial fibrillation 5.75:1) and with age, renal function, and b

52 17 years old, having vagal paroxysmal atrial fibrillation 58 (70%) or neurocardiogenic syncope 25 (30

53 ointe or polymorphic ventricular tachycardia/fibrillation (6% [sustained 3%, nonsustained 3%]), ineff

54 vious heart failure (10% versus 19%), atrial fibrillation (6% versus 10%), and chronic obstructive pu

55 3,426 (15.3%) people, including 6,013 atrial fibrillation, 7,727 heart failure, and 2,809 acute myoca

56 ied considerably according to rhythm (atrial fibrillation 8.03:1; no atrial fibrillation 5.75:1) and

57 (n = 123, 66%) more commonly had ventricular fibrillation (8 cases vs. 0 cases; p = 0.053), and both

58 In persistent atrial fibrillation, a positive correlation was found between t

59 reatment with antiarrhythmic drugs or atrial fibrillation ablation after randomization.

60 hreshold of $100 000 per QALY gained, atrial fibrillation ablation was found to be economically favor

61 n an unselected population undergoing atrial fibrillation ablation with low fibrosis burden.

62 mportant predictor of recurrence post-atrial fibrillation ablation.

63 re (BP) control or anticoagulation in atrial fibrillation (AF) (Trial 2).

64 CLOSE-guided atrial fibrillation (AF) ablation is based on contiguous (inter

65 ransesophageal echocardiograms before atrial fibrillation (AF) ablation procedures in patients treate

66 Atrial fibrillation (AF) adversely impacts health-related quali

67 Outcomes of postoperative atrial fibrillation (AF) after noncardiac surgery are not well

68 hibitor) in patients with nonvalvular atrial fibrillation (AF) after percutaneous coronary interventi

69 aim was to evaluate, in patients with atrial fibrillation (AF) and acute ischemic stroke, the associa

70 Atrial fibrillation (AF) and atrial flutter (AFL) are associate

71 ity is an independent risk factor for atrial fibrillation (AF) and is associated with a higher AF bur

72 ases, the incidence and prevalence of atrial fibrillation (AF) are rising, justifying the term global

73 Atrial fibrillation (AF) can be maintained by localized intramu

74 Risk prediction models for atrial fibrillation (AF) do not give information about when AF

75 Catheter ablation of persistent atrial fibrillation (AF) has limited success.

76 ntific research on atrial fibrosis in atrial fibrillation (AF) has mainly focused on quantitative or

77 nd focal breakthroughs in humans with atrial fibrillation (AF) have been recently demonstrated using

78 mic and haemorrhagic complications in atrial fibrillation (AF) have been studied, but there are limit

79 difficult to noninvasively phenotype atrial fibrillation (AF) in a way that reflects clinical end po

80 y anti-arrhythmic agents approved for atrial fibrillation (AF) in patients with reduced left ventricu

81 timal timing of catheter ablation for atrial fibrillation (AF) in reference to the time of diagnosis

82 Growing prevalence of atrial fibrillation (AF) in the ageing population and its assoc

83 block in one limb, is associated with atrial fibrillation (AF) induction.

84 Atrial fibrillation (AF) is a highly prevalent cardiac arrhythm

85 Atrial fibrillation (AF) is a major risk factor for stroke, and

86 Atrial fibrillation (AF) is an increasingly prevalent arrhythmi

87 Atrial fibrillation (AF) is associated with a risk of ischemic

88 A very late recurrence (VLR) of atrial fibrillation (AF) is considered present when the first r

89 tment of sleep apnea in patients with atrial fibrillation (AF) is critical.

90 direct oral anticoagulants (DOACs) in atrial fibrillation (AF) is dependent on adherence and persiste

91 Susceptibility to atrial fibrillation (AF) is determined by well-recognized risk

92 The incidence of atrial fibrillation (AF) is higher in patients with diabetes.

93 Atrial fibrillation (AF) is the most common arrhythmia and is a

94 Atrial fibrillation (AF) is the most common clinical arrhythmia

95 Atrial fibrillation (AF) is the most common sustained arrhythmi

96 Atrial fibrillation (AF) is the most common sustained cardiac a

97 Atrial fibrillation (AF) is the most common sustained cardiac a

98 Emerging evidence suggests that atrial fibrillation (AF) may be associated with an increased ri

99 n biomarkers associated with incident atrial fibrillation (AF) may improve the understanding of the p

100 Atrial fibrillation (AF) may occur after an acute precipitant a

101 Atrial fibrillation (AF) often arises from structural abnormali

102 on associates with the progression of atrial fibrillation (AF) pathology and adversely affects AF man

103 Asthma and atrial fibrillation (AF) share an underlying inflammatory patho

104 wer prevalence of clinically detected atrial fibrillation (AF) than whites, despite a higher prevalen

105 trial randomized 2,204 patients with atrial fibrillation (AF) to catheter ablation or drug therapy.

106 rsistent and long-standing persistent atrial fibrillation (AF) treatment led to the development of a

107 Catheter ablation for atrial fibrillation (AF) using point-by-point radiofrequency en

108 g algorithm to identify patients with atrial fibrillation (AF) using text alone.

109 that over 46 million individuals have atrial fibrillation (AF) worldwide, and the incidence and preva

110 vast data sources, the management of atrial fibrillation (AF), a common chronic disease with signifi

111 ity, tobacco use, hypertension (HTN), atrial fibrillation (AF), and chronic obstructive pulmonary dis

112 to treat all patients with persistent atrial fibrillation (AF), and effective adjunctive ablation str

113 treatment strategy for patients with atrial fibrillation (AF), but many experience AF recurrence and

114 ity as an independent risk factor for atrial fibrillation (AF), but the underlying pathophysiological

115 ated with an increased propensity for atrial fibrillation (AF), causing higher mortality than AF or H

116 rt disease (IHD), heart failure (HF), atrial fibrillation (AF), stroke, peripheral artery disease, ca

117 er a 100 genetic loci associated with atrial fibrillation (AF), the most common arrhythmia.

118 Atrial fibrillation (AF), the most common sustained cardiac arr

119 n K antagonists (VKAs) for preventing atrial fibrillation (AF)-related stroke.

120 singly used treatment for symptomatic atrial fibrillation (AF).

121 ral well-characterized goat models of atrial fibrillation (AF).

122 eeding in a cohort with cirrhosis and atrial fibrillation (AF).

123 functional bradyarrhythmias and vagal atrial fibrillation (AF).

124 d predisposition may increase risk of atrial fibrillation (AF).

125 d or prolonged PWD is associated with atrial fibrillation (AF).

126 n shown to detect concurrent episodic atrial fibrillation (AF).

127 itus (T2DM) have an increased risk of atrial fibrillation (AF).

128 nction (SND) is often associated with atrial fibrillation (AF).

129 dreds of genetic loci associated with atrial fibrillation (AF).

130 Ablation is a widely used therapy for atrial fibrillation (AF); however, arrhythmia recurrence and re

131 outcomes for patients with new onset atrial fibrillation after cardiac surgery who are treated with

132 oints were freedom from recurrence of atrial fibrillation (after a 2-week "blanking period") and tota

133 In patients with atrial fibrillation and a bioprosthetic mitral valve, rivaroxab

134 d ratio, 2.0 to 3.0) in patients with atrial fibrillation and a bioprosthetic mitral valve.

135 Coronary Intervention), patients with atrial fibrillation and a recent acute coronary syndrome and th

136 n vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutan

137 usual care among patients with early atrial fibrillation and cardiovascular conditions.

138 es such as hypertension, cholesterol, atrial fibrillation and changes in kidney function, left ventri

139 Among patients with atrial fibrillation and CrCl 25 to 30 mL/min, apixaban caused l

140 Atrial fibrillation and delirium are common consequences of car

141 new users of oral anticoagulants with atrial fibrillation and estimated glomerular filtration rate >=

142 Among patients with paroxysmal atrial fibrillation and hypertension, renal denervation added t

143 r early-onset coronary heart disease, atrial fibrillation and prostate cancer.

144 In AUGUSTUS, 4614 patients with atrial fibrillation and recent acute coronary syndrome or percu

145 ed for the treatment of patients with atrial fibrillation and rheumatic heart disease, for the treatm

146 Among patients with permanent atrial fibrillation and symptoms of heart failure treated with

147 ural changes have significant effects on hCT fibrillation and that understanding these effects can in

148 ne reduces the incidence of new-onset atrial fibrillation and the incidence of delirium.

149 ep, cerebrovascular disease, frailty, atrial fibrillation and vitamin C).

150 ), including coronary artery disease, atrial fibrillation, and heart failure, was more prevalent in p

151 ers between patients with and without atrial fibrillation, and increases substantially with increasin

152 e 3-incision technique, no history of atrial fibrillation, and ischemic cause.

153 d endarterectomy, anticoagulation for atrial fibrillation, and patent foramen ovale closure.

154 hypertension, cholesterol, diabetes, atrial fibrillation, and primary prevention guidelines.

155 , followed by coronary heart disease, atrial fibrillation, and stroke.

156 e screening and primary prevention of atrial fibrillation, and whether biological pathways involved i

157 lic hypertension, with versus without atrial fibrillation, and with versus without diabetes mellitus.

158 improving outcomes in heart failure, atrial fibrillation, and, in preclinical studies, certain cance

159 Ischemic strokes related to atrial fibrillation are highly prevalent, presenting with sever

160 roke among hemodialysis patients with atrial fibrillation are partially mediated by lower use of anti

161 Four cases of (paroxysmal) atrial fibrillation are presented, two cases of sepsis and one

162 M signals (including in subjects with atrial fibrillation) as the 3-lead system, is equally safe and

163 reased the likelihood of freedom from atrial fibrillation at 12 months.

164 ixaban with warfarin in patients with atrial fibrillation at an increased risk of stroke.

165 rrence of any atrial tachyarrhythmia (atrial fibrillation, atrial flutter, or atrial tachycardia) bet

166 tabase using MedDRA preferred terms ("atrial fibrillation," "atrial flutter").

167 ncluding age, male gender, paroxysmal atrial fibrillation, basal QTc values, basal heart rate and dua

168 over age and sex in type 2 diabetes, atrial fibrillation, breast cancer and prostate cancer, and ove

169 a 2-week "blanking period") and total atrial fibrillation burden (proportion of time in atrial fibril

170 In patients with atrial fibrillation but lower CHA(2)DS(2)-VASc scores, the GRS

171 ging Research in Genomic Epidemiology Atrial Fibrillation), C(2)HEST (coronary artery disease or chro

172 hmias related to inflammation such as atrial fibrillation can also be expected, in addition to the br

173 opathy characterized by high rates of atrial fibrillation, conduction disease, advanced heart failure

174 heart disease, aortic valve disease, atrial fibrillation, congenital heart disease, various cardiomy

175 aged 60 years or older with permanent atrial fibrillation (defined as no plan to restore sinus rhythm

176 ed cardiac monitoring for subclinical atrial fibrillation detection through smartphone applications o

177 domly assigned patients who had early atrial fibrillation (diagnosed <=1 year before enrollment) and

178 o clinical factors improved new-onset atrial fibrillation discrimination in a multivariable logistic

179 history, and development of new-onset atrial fibrillation during the first four days of ICU admission

180 llation burden (proportion of time in atrial fibrillation) during 6 months of follow-up.

181 Improvements in Atrial Fibrillation Effect on Quality-of-Life scores were signi

182 ted with heart failure, ischemia, and atrial fibrillation, enhance Na(+) influx, generating a late Na

183 ion to Catheter Ablation to Eliminate Atrial Fibrillation (ERADICATE-AF) trial was an investigator-in

184 g age, sex, body mass index, existing atrial fibrillation, existing heart failure, diabetes mellitus,

185 to 80 years of age who had paroxysmal atrial fibrillation for which they had not previously received

186 atients with four arrhythmia classes: atrial fibrillation, general supraventricular tachycardia, sinu

187 O) to prevent stroke in patients with atrial fibrillation has been evaluated in 2 randomized trials;

188 used to reduce thromboembolic risk in atrial fibrillation, have been incriminated as probable cause o

189 ebral SVD with large vessel atheroma, atrial fibrillation, heart failure, and heart valve disease.

190 ratio [HR], 5.6 [95% CI, 2.3-13.5]), atrial fibrillation (HR, 2.6 [95% CI, 1.7-3.5]), and left ventr

191 stry for Better Informed Treatment of Atrial Fibrillation II Registry from 2013 to 2016, 741 underwen

192 modulates phase separation and promotes PrP fibrillation in a NA structure and concentration-depende

193 leotide polymorphisms associated with atrial fibrillation in ambulatory studies using a Sequenom plat

194 anism by which LLPS can regulate the rate of fibrillation in mixtures containing tau isoforms with di

195 monstrated that catheter ablation for atrial fibrillation in patients with heart failure with reduced

196 and who had paroxysmal or persistent atrial fibrillation in sinus rhythm at baseline were randomly a

197 ay impact the way we currently detect Atrial Fibrillation in the general population.

198 lity contributes to risk of new-onset atrial fibrillation in the ICU.

199 rral centers for catheter ablation of atrial fibrillation in the Russian Federation, Poland, and Germ

200 ol therapy in patients with permanent atrial fibrillation, in particular those with coexisting heart

201 High-risk groups of patients with atrial fibrillation include patients with end-stage renal failu

202 pes of genetic analyses performed for atrial fibrillation, including linkage studies, genome-wide ass

203 y stroke prevention for patients with atrial fibrillation, including those with high risk of bleeding

204 nt of ESKD hemodialysis patients with atrial fibrillation, investigating racial/ethnic disparities in

205 bypass graft surgery in patients with atrial fibrillation is associated with a higher rate of 30-day

206 Atrial fibrillation is associated with multiple adverse comorbi

207 Understanding the mechanisms of fibrillation is key to developing rational mitigation st

208 Atrial fibrillation is the most common sustained cardiac arrhyt

209 eptibility to VT/VF (ventricular tachycardia/fibrillation) is difficult to predict in patients with i

210 of individuals with covert paroxysmal atrial fibrillation, is a topic of intensive research interest.

211 hCT fibrillation kinetics was sigmoidal, with lag, growth, a

212 art rates, higher rates of paroxysmal atrial fibrillation, lower platelet count.

213 electrograms during human persistent atrial fibrillation mapping (n=16).

214 omplex time-series, was developed as a novel fibrillation mapping tool and adapted to low spatial res

215 135 centers, 2789 patients with early atrial fibrillation (median time since diagnosis, 36 days) unde

216 spital cardiac arrest (OHCA) and ventricular fibrillation, more than half present with refractory ven

217 The major indication was atrial fibrillation (n = 31 [60%]).

218 ergo surgery (n=25), had a history of atrial fibrillation (n=45), or had no information on the incide

219 ke and Other Thromboembolic Events in Atrial Fibrillation; n=18 201) compared apixaban with warfarin

220 on System for Treatment of Paroxysmal Atrial Fibrillation; NCT03639597) in patients with paroxysmal a

221 y a profile of electrical phenotypes (atrial fibrillation, nonsustained ventricular tachycardia, and

222 ed with electrical phenotypes such as atrial fibrillation, nonsustained ventricular tachycardia, and

223 a favourable option in patients with atrial fibrillation not eligible for oral anticoagulation thera

224 In non-surgical patients with atrial fibrillation, novel oral anticoagulants (NOACs) have bee

225 rted, including erectile dysfunction, atrial fibrillation, obstructive sleep apnoea, osteoporosis and

226 Grade 3-4 atrial fibrillation occurred in one (1%) patient and grade 3-4

227 We recently reported the fibrillation of HN and BAX into beta-sheets.

228 y explain the higher vulnerability to atrial fibrillation of obese patients.

229 eover, time-lapse analysis of Sup35 oligomer fibrillation on cells suggested that the amyloid aggrega

230 contemporary cohort of patients with atrial fibrillation on OAC who underwent cardiac catheterizatio

231 cardiac arrest from ventricular tachycardia/fibrillation or bradyarrhythmias such as atrioventricula

232 idine should not be infused to reduce atrial fibrillation or delirium in patients having cardiac surg

233 as occurrence of postcardiac surgery atrial fibrillation or flutter of at least 30 seconds duration

234 0.59%) for the background population; atrial fibrillation or flutter: 3.44% (95% CI: 3.06% to 3.84%)

235 In patients with atrial fibrillation or other indications for anticoagulation, r

236 No cases of jaw osteonecrosis, atrial fibrillation, or nonhealing fractures were reported.

237 s with coronary artery disease (CAD), atrial fibrillation, or reduced left ventricular function, sugg

238 toperatively, AKI was associated with atrial fibrillation (P = 0.013) and pneumonia (P = 0.005).

239 r patients (p = 0.019) and those with atrial fibrillation (p = 0.066), lower hematocrit (p = 0.084),

240 ardial infarction, heart failure, and atrial fibrillation (P<0.001) and was superior and incremental

241 idence of early de-novo postoperative atrial fibrillation (P=0.003).

242 Postoperative atrial fibrillation (pAF) after coronary artery bypass grafting

243 Paroxysmal atrial fibrillation (PAF) detection was higher in the ICM cohor

244 ents with symptomatic drug-refractory atrial fibrillation (paroxysmal and persistent) undergoing firs

245 nticoagulation-eligible but untreated atrial fibrillation patient.

246 luded 55 paroxysmal and 21 persistent atrial fibrillation patients undergoing either RF/PF (40 patien

247 A total of 333 enrolled persistent atrial fibrillation patients underwent ablation.

248 tion percentage relative to peers for atrial fibrillation patients with elevated stroke risk (CHA(2)D

249 ite improvements in the management of atrial fibrillation, patients with this condition remain at inc

250 (Pulsed Fields for Persistent Atrial Fibrillation [PersAFOne]; NCT04170621).

251 e vs. Novel Anticoagulation Agents in Atrial Fibrillation (PRAGUE-17) was a multicenter, randomized,

252 e vs. Novel Anticoagulation Agents in Atrial Fibrillation [PRAGUE-17]; NCT02426944).

253 ructures are frequent in patient with atrial fibrillation (prevalence: 13.5%).

254 may be a novel therapeutic target for atrial fibrillation prevention and treatment.

255 ting the development of tools to monitor the fibrillation process.

256 iac arrest from shock-refractory ventricular fibrillation/pulseless ventricular tachycardia.

257 r origins in patients with paroxysmal atrial fibrillation receiving catheter ablation.

258 oronary intervention in patients with atrial fibrillation receiving oral anticoagulation.

259 ere was a significantly lower rate of atrial fibrillation recurrence with catheter cryoballoon ablati

260 d rhythm control to the management of atrial fibrillation-related symptoms.

261 The mechanisms sustaining myocardial fibrillation remain disputed, partly due to a lack of ma

262 fects can inform the rational development of fibrillation-resistant hCT analogs.

263 Human patients with persistent atrial fibrillation show sixfold lower levels of myocardial cal

264 atients with OHCA and refractory ventricular fibrillation significantly improved survival to hospital

265 o introduced for stroke prevention in atrial fibrillation (SPAF).

266 relationship between birthweight and atrial fibrillation, supporting the growing body of evidence th

267 central pathophysiological feature of atrial fibrillation that also hampers its treatment; the underl

268 sphorylated hCT analogs that showed modified fibrillation that depended on phosphorylation site.

269 patients with symptomatic paroxysmal atrial fibrillation that has not responded to medication, cathe

270 Atrial fibrillation, the most common cardiac arrhythmia, is an

271 vs. Warfarin for post Cardiac Surgery Atrial Fibrillation: The NEW-AF Trial.

272 treatment for symptomatic, paroxysmal atrial fibrillation, there was a significantly lower rate of at

273 03639597) in patients with paroxysmal atrial fibrillation, this LICU system was evaluated to determin

274 showed that amongst individuals with atrial fibrillation, those with genetically lower levels of fac

275 ion With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) d

276 th symptomatic, paroxysmal, untreated atrial fibrillation to undergo catheter ablation with a cryothe

277 embolism in patients with nonvalvular atrial fibrillation; transcatheter aortic valve replacement in

278 shared decision-making in persistent atrial fibrillation treatment.

279 n vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial [CABANA]; NCT00911508).

280 ersus Antiarrhythmic Drug Therapy for Atrial Fibrillation) trial randomized 2,204 patients with atria

281 real-world registry of patients with atrial fibrillation undergoing cardiac catheterization, most ca

282 short-term outcomes in patients with atrial fibrillation undergoing isolated coronary artery bypass

283 thirty-four consecutive patients with atrial fibrillation undergoing radiofrequency ablation were inc

284 han half present with refractory ventricular fibrillation unresponsive to initial standard advanced c

285 heter could safely and rapidly ablate atrial fibrillation using either a combined RF/PF approach (cap

286 the impact of birthweight on incident atrial fibrillation using summary data from the Early Growth Ge

287 hypertension, myocardial infarction, atrial fibrillation, valvular disease, and revascularization pr

288 index hospitalization, including ventricular fibrillation, ventricular tachycardia (VT), nonsustained

289 nsecutive adults with refractory ventricular fibrillation/ventricular tachycardia out-of-hospital car

290 of FIX-HF-5C2 subjects had permanent atrial fibrillation versus 0% in FIX-HF-5C.

291 prevention of ischaemia-induced ventricular fibrillation (VF).

292 ventricular contraction-induced ventricular fibrillation/VT (29%), and VT could not be induced in 2

293 The median percentage of time in atrial fibrillation was 0% (interquartile range, 0 to 0.08) wit

294 radiofrequency ablation of persistent atrial fibrillation was associated with a significant decrease

295 The time to the onset of fibrillation was extended by more than 10-fold relative

296 years who had mitral valve disease or atrial fibrillation when compared with patients aged less than

297 and prolongs spontaneous episodes of atrial fibrillation, whereas atrial-specific overexpression of

298 irin among patients with both CCS and atrial fibrillation who require anticoagulation.

299 ASTLE-AF study (Catheter Ablation for Atrial Fibrillation With Heart Failure) population.

300 tricular tachycardia (>15 beats); (5) atrial fibrillation with rapid ventricular response; (6) suprav